Scleroderma, Diffuse - 12 Studies Found
Completed |
: Nilotinib in the Treatment of Systemic Sclerosis : Systemic Sclerosis : 2010-07-01 : Drug: Nilotinib (Tasigna) Patients will be treated with Nilotinib 400 mg two times a day for 6 months. |
Active, not recruiting |
: Taking Charge of Systemic Sclerosis : Scleroderma : 2015-05-22 :
|
Completed |
: Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis : Systemic Sclerosis : 2007-11-07 : Drug: Imatinib Mesylate In initial phase, patients will be treated with Gleevec 400 mg daily for 12 mont |
Completed |
: Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis : Systemic Sclerosis : 2008-04-25 |
Recruiting |
: Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis : Scleroderma : 2012-06-18 : Drug: Campath Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the incl |
Completed |
: Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis : Systemic Sclerosis : 2008-04-23 |
Completed |
: A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) :
|
Completed |
: Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement : Scleroderma, Systemic : 2006-06-02 : Drug: Mycophenolate mofetil |
Recruiting |
: Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial : Scleroderma : 2011-09-29 :
|
Completed |
: Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial : Systemic Scleroderma : 2015-01-18 :
|